Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Regeneron Pharmaceuticals, Inc. ( REGN ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:05 PM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Marion McCourt - Executive Vice President of Commercial Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Morgan Stanley, Research Division All right. Good afternoon, everybody. Thanks for joining us. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Very pleased to be hosting Regeneron this afternoon. Joining us from the company, we have Chris Fenimore, EVP, Finance and CFO; Marion McCourt, EVP and Head of Commercial; and Ryan Crowe, SVP, IR and Portfolio Strategy and Intelligence. I'm going to turn it over to Ryan for his disclosures, and then we'll get started. But thanks so much for being here. Ryan Crowe Senior Vice President of Investor Relations & Strategic Analysis Terence, thanks for having us. Always a pleasure to be here at the Morgan Stanley Healthcare Conference. I have a quick disclaimer to read as well, and then we'll get started. I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. With that, Terence, let's get started. Question-and-Answer Session Terence Flynn Morgan